Patrick Taylor: Yes, I’ll respond first and then Eduardo with a bit more detail. Actually, generally, well received, I mean, both in terms of elimination, everybody understands that it’s important for mutual value creation. We see movement into other SKUs. And also as we’ve done SKU standardization across retailers, because we saw changes in pack sizes, lid sizes, labeling, font sizes, all of which was driving tremendous complexity that just wasn’t serving the consumer or driving preference. So this basically has allowed us to create more value without really any risk or trade out. So I think so far, the effort has gone extremely well. We continue to be very focused on the U.S. to the question earlier about gross margin expansion, the opportunity for further pricing. And we continue to work that through with our retailers, even looking into 2024.
Eduardo Bezerra: Yes, and just to compliment to what Patrick mentioned is, as we highlighted, so we achieved already 750 of the 1000 SKUs planned for this year to be simplified. And so the reaction has been very positive in that sense. And we continue to our conversations with them to progress in those areas. So I think that’s been very well implemented and very well communicated with the retailers at this stage.
Daniel Biolsi: Thanks, Daniel.
Operator: [Operator Instructions] Our next question comes from Keonhee Kim from Morning Star. Please go ahead with your question.
Keonhee Kim: Hey guys, thanks for taking my question here. I wanted to follow up on Opill. I assume the launch of that product will be maybe a little bit dilutive for some time through marketing and SG&A spending. But it’ll eventually get to neutral or even accretive. And so I was wondering how big of a headwind should we expect from this launch, if any?
Eduardo Bezerra: Well, so the way we were, we were thinking about Opill, on the launch, so we expected the selling to take place in Q1, maybe because we wanted to make sure there is continuity on the product supply based on the anticipated customer repair changing levels. But as you know, it was highlighted, we want to make sure that we invest in the franchise of the whole women’s health category. We expect that to be dilutive in 2024.
Patrick Taylor: It’s an important question that I think is probably going to come up at some stage. Have we considered that in our balance earning per share growth for 2024, yes, and yes, we have. We still strongly outlook performance in the 2.90 to 3 range. So even though this will be dilutive, that’s standard of any brand launch, the program continues to build well, but it’s just part of a sort of balance set of investments and opportunities as we continue with double digit earning per share growth.
Keonhee Kim: Great, that’s really helpful. And just one more from me. Can you talk about how much more SKU prioritization is left over? And should we expect any of that for 2024? Thank you.
Patrick Taylor: I’m sorry, SKU prioritization. We will continue with these efforts of driving growth margin by focusing on more value of creative offerings. So I would expect some effect into 2024. But I would expect less revenue impact as we balance that with growth initiatives to a greater extent than we have in 2023.
Eduardo Bezerra: Yes, just to compliment there, as you remember, in 2024, we have additional benefit from the supply chain reinvention program. That’s mainly because of the other pillars that we have there into our plans.
Operator: And ladies and gentlemen at this time, I’m showing no additional questions, I’d like to turn the floor back over to the management team for any closing remarks.
